3. Acquisition and licensing: MoGen had completed several acquisition and licensing deals that had helped it achieve the strong growth in revenues and earnings per share (EPS), The company expected to continue this strategy an had projected to complete a purchase of Genix, Inc., in 2006 for approximately $2 billion expertise in the discovery, development, and manufacture of human therapeutic antibodies.